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A B S T R A C TObjective: To estimate the cost for the management of chronic
hepatitis C (CHC) and related morbidities by using a payer perspec-
tive in Thailand. Methods: Data elements were extracted from
medical records of 542 patients newly diagnosed with CHC in ﬁve
tertiary care hospitals across Thailand. All patients were divided into
ﬁve health states: noncirrhotic CHC, hepatitis C virus (HCV)-related
compensated cirrhosis, HCV-related decompensated cirrhosis, HCV-
related hepatocellular carcinoma, and HCV-related liver transplanta-
tion. Resource utilization data for each patient during a 12-month
follow-up study period were compiled, and reference prices pub-
lished by the Thai government were used to estimate the cost for
each health state. The average cost was calculated and categorized
into various groups, for example, laboratory and diagnostic tests,
procedures, medication, and hospitalization. Results: The average
number of outpatient visits per patient was approximately six visits
in all cohorts. The HCV-related hepatocellular carcinoma and liver
transplantation cohorts had a higher average number of inpatientsee front matter Copyright & 2014, International S
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ai University, 239 Huay Kaew Road, Muang Districadmissions per patient. The average number of days per admission
varied from fewer than 3 days to 1 week or more across all the health
states. The average annual total cost per patient varied across all
health states from approximately 170,000 to 600,000 baht, and
medication cost was the largest portion in every cohort, except the
HCV-related liver transplantation cohort in year 1. Among all med-
ications, the average annual antiviral medication cost per patient
was the largest portion in the noncirrhotic CHC and HCV-related
compensated cirrhosis cohorts. Conclusions: CHC was a costly dis-
ease in Thailand. The average annual medication cost was the
largest portion in every health state, except HCV-related liver
transplantation.
Keywords: direct medical cost, economic burden, hepatitis C virus,
resource utilization.
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Hepatitis C virus (HCV) infection is a major disease burden on the
world that affects 130 to 170million people worldwide [1]. The disease
can result in signiﬁcant morbidities and mortality among infected
patients. Seventy percent of HCV-infected patients will develop
chronic infection [1]. Approximately 25% of these patients ultimately
develop cirrhosis, and annually 1.6% of them develop hepatocellular
carcinoma (HCC) [2–4]. Among the patients with cirrhosis, the annual
rate of decompensation is about 4%, and its annual death rates are
15% and 30% in industrialized and developing countries, respectively
[4]. For patients with HCC, the annual death rate depends on access to
treatment and is estimated to be approximately 80% to 90% [4].
Currently, the standard treatment for chronic hepatitis C (CHC) is
a combination of a weekly peginterferonalfa and daily oral ribavirin
for approximately 1 year. The goal of CHC treatment is to have thehighest overall sustained virological response rate [5–7]. Several
factors including patient preferences, patient age, duration of
infection, viral genotypes, HCV RNA levels, and presence of symp-
toms are considered when deciding whether or not to treat CHC.
Generally, treatment is recommended for patients with moderate
and severe CHC. In patients with a milder degree of disease,
treatment is usually deferred and only monitoring of liver disease
progression by biopsy at an interval of 4 to 5 years is required [8].
In Thailand, HCV infection is an important disease with a
prevalence of approximately 1.8% across age groups and areas. The
prevalence is higher in people older than 60 years (5%) and HIV-
infected patients (7.8%) [9,10]. Given that CHC and its subsequent
morbidities and mortality could result in a high burden on the
country, understanding the economic implications of CHC and
related morbidities is crucial for determining health policies on
resource allocation. Because Thailand’s health care system isociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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burden from CHC are available, namely, in terms of practice styles,
drug cost, payment systems, and population’s characteristics, the
country should have its own calculations. The data will not only
have a profound impact on initial decision making but can also be
used for further economic evaluation, for example, cost-effectiveness
or cost-utility analysis. Therefore, this study was conducted with the
objective to estimate the cost for the management of CHC and
related morbidities by using a payer perspective in Thailand.Methods
Study Design
This study was part of a retrospective and multicenter survey for
resource utilization and outcomes in the management of patients
with CHC and related morbidities in various health states in
Thailand. Data on the real-world use of health care resources,
including medications related to CHC and its complications per
clinical discretion of the prescribing physician, were collected
from the existing medical records. Because the majority of Thai
people used public health care services, collecting data from
public sector would be more meaningful to policymakers and
payers, ﬁve major public tertiary care hospitals from urban and
upcountry areas across Thailand were purposively recruited.
All patients who were newly diagnosed with CHC were
identiﬁed by hepatologists at each study hospital during the
study period (December 2007 through May 2008). The source of
patient identiﬁcation was the list of patients who were diagnosed
with one of the ﬁve health states, namely, noncirrhotic CHC,Example 1: A patient with initial diagnosis of noncirrhot
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Fig. 1 – Examples for possible data collection periods ( ). CH
carcinoma; HCV, hepatitis C virus; LF, last follow-up; LT, liver tranHCV-related compensated cirrhosis, HCV-related decompensated
cirrhosis, HCV-related HCC, and HCV-related liver transplanta-
tion, during the years 2003 to 2004. All medical records were
reviewed before the beginning of data collection to ensure
patients’ eligibility criteria and completeness of the data.
The diagnostic criteria for CHC in this study were either
positive results of anti-HCV from enzyme immunoassay or con-
ﬁrmatory testing (e.g., recombinant immunoblot assay) or positive
results of HCV RNA from real-time polymerase chain reaction.
Patients diagnosed with CHC but showing no evidence of cirrhosis
were identiﬁed as noncirrhotic CHC cohort. Patients with HCV-
related compensated cirrhosis were identiﬁed by biopsy, ultra-
sound, or some clinical signs, for example, portal hypertension,
whereas patients with HCV-related decompensated cirrhosis were
those who had the appearance of at least one episode of ascites,
jaundice, encephalopathy, or variceal bleeding but did not show
any evidence of HCC. Patients in the HCV-related HCC cohort were
identiﬁed in accordance with HCC deﬁned in the 2005 American
Association for the Study of Liver Diseases practice guideline.
Patients who had undergone HCV-related liver transplantation
were classiﬁed into the HCV-related liver transplantation cohort.
If there was a recent change in the patient’s health state, the
earliest health state was chosen to attain data of a single health
state covering at least 12 months after diagnosis.
Eligible patients were required to have one of the ﬁve health
states and to have available follow-up data for a 12-month period
after the diagnosis of the health state, except for patients with HCC
and liver transplantation in which the period of the available data
could be less than 12 months. In addition, they had to have follow-
up data in the speciﬁed period after being diagnosed with each
health state (Fig. 1). Patients with noncirrhotic CHC and HCV-relatedic CHC in 2004 
70026002
ompensated cirrhosis in 2003 and a diagnosis 
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after diagnosis. Patients with HCV-related decompensated cirrhosis
had to have follow-up data within 3 months after diagnosis.
Patients with HCV-related HCC and HCV-related liver transplanta-
tion had to have follow-up data within 8 weeks after diagnosis or
liver transplantation. These cutoffs were based on expert opinions
that patients who had follow-up data later than the speciﬁed
periods did not represent the normal practice pattern in Thailand
and would confound resource utilization. The criteria excluded any
patient who was involved in clinical trials or who had hepatitis B
virus coinfection or who had clinical or known acute hepatitis A
virus or hepatitis D virus infection or who had known human
immunodeﬁciency virus or who had knownmedical conditions that
were contraindicated to HCV treatment. A Web-based case report
form was used for data collection. The data were collected from the
time of initial diagnosis of a particular health state to the last
follow-up visit or death.
Data Collection
The data were collected from patients’ medical records. The use
of these records was approved by each hospital’s institution
review board. Data on demographic characteristics, diagnosis
dates, baseline characteristics, treatments and their outcomes,
and resource utilization were extracted from the patients’ med-
ical records. The demographic data included patient’s date of
birth, sex, race, occupation, and payment type. Baseline charac-
teristics included patient’s weight, HCV genotype, ﬁbrosis or
cirrhosis, and comorbidities. Treatments included patient’s med-
ications, and their outcomes comprised sustained virological
response, progression to cirrhosis, and progression to HCC. The
resource utilization of this study included all medical-related
resources, for example, diagnostic and laboratory tests, proce-
dures, inpatient admission, outpatient visits, as well as medica-
tions for HCV treatment and related morbidities.
The diagnostic and laboratory test comprised a number of
various tests in a year, for example, alanine aminotransferase,
alkaline phosphatase, anti-HCV, and HCV viral load. Data on the
number of procedures, for example, liver biopsy, computed
tomography scan, magnetic resonance imaging, hemihepatec-
tomy, and liver transplant, were collected. The inpatient admis-
sion data included the hospital admitted and discharged dates
and the total number of admissions in a year. Data on the
number of visits with general practitioners and gastroenterolo-
gists and to emergency room were collected from outpatient
data. Data on the total amount of medications that patients
obtained in a year, including both antiviral and other medica-
tions, were also compiled.
Statistical Analysis
All data were analyzed by using SAS, version 9.1.3 (SAS Institute,
Inc., Cary, NC). Baseline patient characteristics were descriptively
analyzed. All resource utilization data for each patient during the
12-month follow-up study period were compiled for each health
state and on annual basis. The number of annual outpatient visits
per patient, inpatient admissions per patient, and average length
of stay days per admission were calculated to reﬂect the volume
of utilization across the health states. Reference prices published
by the Ministry of Public Health and the Ministry of Finance,
Thailand, were used for estimating costs. These reference prices
were a good measure for this study because the data were
obtained from public hospitals. All the costs were adjusted to
2008 US dollar (35 Thai baht ¼ US $1). Inﬂation adjustment to 2008
was performed on the basis of Thailand Consumer Price Index.
The costs were stratiﬁed into laboratory and diagnostic tests,
procedures, medication, and hospitalization for each health state.Results
Patient characteristics across ﬁve HCV-related health states are
shown in Table 1. A total of 542 patients were included in this
study. Almost 55% of these patients were included in the non-
cirrhotic CHC cohort, while 25% of the recruited patients were
diagnosed with HCV-related compensated cirrhosis. The rest of
the patients or approximately 20% were in either the HCV-related
decompensated cirrhosis cohort or the HCV-related HCC cohort.
The proportion between male and female patients varied across
all cohorts. Among all cohorts, the noncirrhotic CHC cohort was
the youngest, with an average age of 49.4 years. Interestingly,
patients covered by the Civil Servant Medical Beneﬁt
Scheme (CSMBS) and the state enterprise were the largest group
in every cohort. Most of the patients’ HCV genotype in this study
was genotype 3, and a number of patients’ genotypes were still
unidentiﬁed, especially those of patients in the more severe
health states. More than half of each cohort, except the HCV-
related liver transplantation cohort, had no other comorbidity.
Table 2 shows the level of outpatient and inpatient utiliza-
tions across the health states. The average number of annual
outpatient visits per patient among all cohorts was slightly
different at around six to seven visits. For inpatient service, the
HCV-related HCC and liver transplantation cohorts had signiﬁ-
cantly higher average number of inpatient admissions or hospi-
talizations (1–1.34 admissions) per patient than did other cohorts
with less severe disease (0.08–0.35 admissions). While the aver-
age number of days that patients stayed in the hospital per
admission was approximately fewer than 3 days for the non-
cirrhotic CHC and HCV-related compensated cirrhosis cohorts,
the other cohorts on average stayed about 1 week or more per
each admission.
Table 3 shows the average annual cost per patient for each
resource category by each HCV-related health state. The average
annual total cost per patient varied across all ﬁve health states
from approximately US $4,900 to more than US $17,000. Among
these health states, the HCV-related liver transplantation cohort
had the highest average total annual cost per patient, particularly
in year 1. The average annual total cost per patient of non-
cirrhotic CHC and HCV-related compensated cirrhosis cohorts
was about the same but higher than that of HCV-related decom-
pensated cirrhosis and HCC cohorts. The medication cost was the
highest portion of the annual cost per patient in every cohort,
and it declined while the health states became more severe,
except the HCV-related liver transplantation cohort in year 1.
There were two different sources of average annual medication
cost among these health states. The average annual antiviral
medication cost per patient of the noncirrhotic CHC and HCV-
related compensated cirrhosis cohorts was much higher than
their average annual cost per patient of other medications. In
contrast, the HCV-related decompensated cirrhosis and HCC
cohorts had lower average annual antiviral medication cost per
patient, but their cost of other medications was higher. The HCV-
related liver transplantation cohort in both their year 1 and later
did not use the antiviral medications at all.
When the patients’ health states became worse, the average
annual procedure cost per patient tended to increase. It was
especially high for the HCV-related HCC and liver transplantation
cohorts. It should be noted that the average annual procedure
cost per patient of the HCV-related liver transplantation cohort
was tremendously high, and, in fact, higher than the other
average total annual costs per patient. The average annual cost
per patient for laboratory and diagnostic tests was not relatively
high in all cohorts. The cost of laboratory and diagnostic tests,
however, was highest for the HCV-related liver transplantation
cohort. The average annual cost per patient of hospitalizations
Table 1 – Patient characteristics across HCV-related health states.
Noncirrhotic
CHC (N ¼ 297;
54.80%)
Compensated
cirrhosis (N ¼ 136;
25.10%)
Decompensated
cirrhosis (N ¼ 64;
11.81%)
Hepatocellular
carcinoma
(N ¼ 43; 7.93%)
Liver
transplantation
(N ¼ 2; 0.37%)
Sex, n (%)
Female 133 (44.8) 68 (50.0) 39 (60.9) 17 (39.5) 1 (50.0)
Male 164 (55.2) 68 (50.0) 25 (39.1) 26 (60.5) 1 (50.0)
Age (y), mean 
SD
49.4  9.3 53.5  8.8 54.6  12.8 58.1  8.9 56.0  8.9
Reimbursement
scheme, n (%)
CSMBS 211 (71.2) 73 (53.9) 29 (44.6) 22 (50.0) 2 (100)
UC Scheme 13 (4.3) 28 (20.6) 19 (30.8) 11 (27.3) 0
SSS 9 (3.0) 2 (1.4) 0 2 (4.5) 0
Self-pay 58 (19.5) 32 (23.4) 16 (24.6) 7 (15.9) 0
Others 6 (2.0) 1 (0.7) 0 1 (2.3) 0
Genotype
Genotype 1 128 (43.1) 33 (24.3) 11 (17.2) 7 (16.3) 0
Genotype 3 148 (49.8) 85 (62.5) 12 (18.8) 6 (14.0) 1 (50)
Others 5 (1.7) 0 0 1 (2.3) 0
NI 16 (5.4) 18 (13.2) 41 (64.1) 29 (67.4) 1 (50)
No. of comorbidities
0 188 (63.3) 73 (53.7) 42 (65.6) 27 (62.8) 0
1 66 (22.2) 38 (27.9) 12 (18.7) 8 (18.6) 1 (50)
2 34 (11.4) 17 (12.5) 6 (9.4) 8 (18.6) 1 (50)
3 7 (2.4) 6 (4.4) 3 (4.7) 0 0
4 2 (0.7) 2 (1.5) 1 (1.6) 0 0
CHC, chronic hepatitis C; CSMBS, Civil Servant Medical Beneﬁt Scheme; HCV, hepatitis C virus; NI, not identiﬁed; SSS, Social Security Scheme;
UC, Universal Coverage.
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health state, and its amount increased when the health states
became worse.Discussion
This study was the ﬁrst estimation of a direct economic burden of
CHC on Thailand. Almost 80% of the patients were found in the
ﬁrst two less severe states, which were the noncirrhotic CHC and
HCV-related compensated cirrhosis cohorts. This ﬁnding wasTable 2 – Annual utilization of outpatient and inpatient h
states.
Noncirrhotic
CHC
(N ¼ 297)
Compensated
cirrhosis
(N ¼ 136)
Deco
cirrho
(N ¼
Average number of
OP visits per
patient
6.56  2.42 6.33  2.43 6.2
Average number of
IP admissions per
patient
0.10  0.20 0.08  0.24 0.3
Average length of
stay per
admission (d)
1.01  0.93 2.57  2.03 8.6
Note. Values are mean  SD.
CHC, chronic hepatitis C; HCV, hepatitis C virus; IP, inpatient; OP, outpacorrelated with the nature of CHC disease [2–4]. The noncirrhotic
CHC cohort was slightly younger than the other cohorts, and the
average age tended to be higher in the more severe health states.
This result was consistent with the natural history of HCV
infection, which is age-dependent, and the older age at infection
was associated with the increased rate of ﬁbrosis progression
[1,11]. For reimbursement schemes, there are three public health
insurance schemes in Thailand, including the CSMBS for all
government employees, dependents, government retirees, and
state enterprise employees; the Social Security Scheme (SSS) for
private sector employees; and the Universal Coverage Scheme forospital services per patient across HCV-related health
mpensated
sis
64)
Hepatocellular
carcinoma
(N ¼ 43)
Liver transplantation
(N ¼ 2)
Year 1 Year 2þ
1  2.24 7.07  3.84 6.50  3.54 6.25  2.47
5  0.70 1.34  1.56 1.00  – –
9  16.32 6.21  5.44 15.50  4.95 –
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CSMBS beneﬁciaries were the largest group of the patients in
every cohort of this study, which was inconsistent with the fact
that the Universal Coverage Scheme was the largest public
insurance with 75% of population coverage while the SSS and
the CSMBS covered only 15% and 8% of the Thai population,
respectively. A reason could be that the payment type of the
CSMBS was fee for service while the other schemes used
capitation payment. All medical costs could be reimbursed for
the CSMBS, which allowed CSMBS beneﬁciaries to access more
health care services, particularly in tertiary care hospitals where
this study was conducted. This study also identiﬁed the patients’
HCV genotypes, and the results showed that the genotypes were
consistent with previous epidemiology studies in Thailand,
which indicated that the most prevalent genotype of HCV among
the Thai population was genotype 3 [12,13]. This conﬁrmed that
the prevalence of the HCV genotype in Thailand is different from
that in other Southeast Asian countries, in which the majority of
the HCV genotype was type 1 [14]. Overall, most patient charac-
teristics of this study were consistent with the nature of CHC
disease and epidemiology in Thailand. So, the selection condi-
tions had little effect on the representativeness of the patient
sample.
The similar annual numbers of outpatient visits per patient
across all cohorts indicated that no matter how severe the CHC
was, the patients on average saw their doctors every 2 months.
Severity, however, seemed to be a good explanation of other
results of resource utilization. Less severe patients, including the
noncirrhotic CHC, HCV-related compensated cirrhosis, and HCV-
related decompensated cirrhosis cohorts, were admitted to hos-
pitals less often and tended to stay in the hospital shorter than
did more severe patients, including the HCV-related HCC and
liver transplantation cohorts. No previous study reported
resource utilization of each HCV-related health state. The results
of each health state in this study, however, were not largely
different from the results of a recent study in the United States,
which revealed that the overall chronic HCV average number of
annual hospital admissions and annual inpatient days was 0.46
times and 7.74 days, respectively [15].
The average annual total direct cost per patient for every
cohort in this study enormously exceeded that of some health
conditions in Thailand such as diabetes (approximately US
$185.71) and road trafﬁc injuries (approximately US $94.29)
[16,17]. These results indicated that the direct economic burden
of CHC was very high and demanded policymakers’ attentions.
The HCV-related liver transplantation cohort had the highest
average annual total cost per patient driven by the cost of
medical procedures. The cost of medications was a major
component driving the overall total cost of patients with CHC.
Basically, the goal of CHC treatment is to prevent complications
of HCV infection [8]. Thai hepatologists recommended that HCV-
infected patients, who are in the noncirrhotic CHC with abnormal
alanine aminotransferase and HCV-related compensated cirrho-
sis cohorts, should be treated by antiviral medications, for
example, peginterferon and ribavirin [18]. The cost of these
antiviral medications was relatively high, and their treatment
periods were long. Undoubtedly, they were the major cost of the
ﬁrst two cohorts. The proportions of these antiviral medication
cost to the overall cost, which was approximately more than 90%,
were similar to those of two studies in the United States [19,20].
Other medications played more important roles in HCV-related
decompensated cirrhosis, HCV-related HCC, and HCV-related
liver transplantation. Thai hepatologists suggested considering
liver transplantation, instead of antiviral treatments, for the
HCV-related decompensated cirrhosis cohort [18]. This might
explain why the average annual antiviral medication cost
dropped considerably in this cohort. Similarly, the average
V A L U E I N H E A L T H R E G I O N A L I S S U E S 3 C ( 2 0 1 4 ) 1 2 – 1 8 17annual cost of antiviral medications in the HCV-related HCC and
liver transplantation cohorts was very low while the cost of other
medications went up.
Various laboratory and diagnosis tests for monitoring
patients’ responses to antiviral medications were recommended.
Moreover, periodic liver biopsies were recommended for patients
in these two health states who might be unwilling to undergo
antiviral treatments [21]. These contributed to the relatively
higher average annual laboratory and diagnostic test cost for
noncirrhotic CHC and HCV-related compensated cirrhosis
cohorts compared with those of HCV-related decompensated
cirrhosis and HCC cohorts.
The average annual procedure cost per patient increased
when the health states became more severe. Its amounts were
higher than the average annual total cost of every cohort, and
thus the HCV-related liver transplantation cohort had the highest
average annual total cost per patient. Even though the sample
size of this cohort was very small, the relatively high cost of liver
transplantation should be brought to policymakers’ attention.
Policymakers needed to consider a trade-off between providing
expensive antiviral medications to patients newly diagnosed
with noncirrhotic CHC or HCV-related compensated cirrhosis
and saving antiviral costs but taking future risks of patients
progressing to more severe disease stages, which might lead to
higher costs from liver transplantation or patient’s death.
The average annual cost of hospitalization per patient was the
lowest when compared with other costs in every health state.
This result was inconsistent with results from a study conducted
in the United States, which indicated that hospitalization was
one of the key cost drivers [15]. This ﬁnding, however, was
reasonable because the hospitalization cost in Thailand was
much lower than in the United States due to the lower labor
cost. The increases in average annual hospitalization cost per
patient in more severe health states were concordant with the
inpatient service utilization shown in Table 2 that patients in
later health states tended to have a higher number of inpatient
admissions and longer length of stays.
There were several limitations to this study. First, the
retrospective study design could result in incomplete data.
Retrospective study design, however, was considered the most
appropriate due to the time and budget limitations. Second, the
small sample size, especially the HCV-related liver transplan-
tation cohort, could cause some biases. This might reﬂect,
however, the real situation in Thailand in which few patients
underwent liver transplantation because of both clinical and
ﬁnancial reasons. Third, the generalizability of study results
might be limited. Because Thailand’s health care system,
economic structure, and CHC patient characteristics differ from
those of many other countries, these factors should be consid-
ered in generalizing and applying the results to other countries
because resource utilization for CHC and related morbidities
depended very much on these factors. In addition, all patients
in this study were from tertiary care hospitals, which were
usually well equipped with technology and experts. The deci-
sion on treatments and/or other tests in provincial hospitals,
district hospitals, or primary health care units could be different
from those in these high-level hospitals. Fourth, the medical
cost in this study was not speciﬁc only to CHC disease due to
possible confounding factors from patients’ other comorbid-
ities. The majority of the patients in every cohort, except the
HCV-related liver transplantation cohort, had no other comor-
bidities during the data collection periods. Fifth, the study
collected data only from patients newly diagnosed with CHC
and related morbidities. The costs and resource utilization
could have been different if we had included data from patients
with related morbidities progressing from CHC. Finally, all costs
in this study were estimated from reference prices establishedby the Ministry of Public Health and the Ministry of Finance.
The reference prices suited the study perspective, but they
might or might not have reﬂected real-world unit prices. They
were the best estimation, however, unless the microcosting
method, which would require large amount of resources,
was used.Conclusions
This study showed that CHC was one of the costly diseases
in Thailand, and it could become more costly if liver cirrhosis
developed and eventually required liver transplantation.
Despite some limitations, the study generated interesting points
to policymakers and payers that early proper CHC treatment
might help to prevent more costs as the disease progresses
to more advanced stages. Future research should focus on not
only amending the study limitations but also extending the
study results. Indirect costs attributable to any HCV-related
health states should be investigated to capture the societal
perspective of the CHC treatments. A full economic evaluation
of antiviral medications, for example, cost-effectiveness analy-
sis, and their budget impact analysis for the country were also
recommended.
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